AstraZeneca Pharma India Limited has announced a postal ballot seeking shareholder approval for material related party transactions worth ₹3,900 crore for the financial year 2026-27. The company issued the postal ballot notice on February 11, 2026, with the cut-off date for determining eligible shareholders set as February 20, 2026.

Proposed Related Party Transactions

The pharmaceutical company seeks approval for two significant related party transactions through ordinary resolutions:

Transaction with AstraZeneca UK Limited

The first resolution proposes transactions worth ₹2,400 crore with AstraZeneca UK Limited, the parent company in the corporate structure. This amount represents 140% of the company's annual turnover for the financial year 2024-25. The transactions will cover purchase, transfer, or receipt of products, goods, materials, services, reimbursement and recovery costs, and transfer pricing obligations.

Transaction with AstraZeneca AB, Sweden

The second resolution seeks approval for transactions valued at ₹1,500 crore with AstraZeneca AB, Sweden, representing 87% of the annual turnover for financial year 2024-25. Similar to the UK entity, these transactions encompass the same range of business activities including product purchases, material transfers, and service arrangements.

E-Voting Schedule and Process

The company has established a comprehensive timeline for the postal ballot process:

Shareholders whose names appear in the Register of Members or List of Beneficial Owners as of the cut-off date will be eligible to participate in the e-voting process. The company has engaged National Securities Depository Limited (NSDL) to facilitate secure electronic voting.

Corporate Governance and Compliance

The proposed transactions align with the company's ordinary course of business in manufacturing and marketing pharmaceutical products. Both transactions have been reviewed and approved by the Audit Committee, which confirmed that the arrangements are conducted on an arm's length basis without any special benefits or privileges extended to the related parties.

Mr. Vijayakrishna K.T, a practicing Company Secretary from Bengaluru, has been appointed as the Scrutinizer to conduct the postal ballot process in a fair and transparent manner. The Scrutinizer will submit the final report to the Chairperson by March 31, 2026.

Business Rationale

The company stated that these transactions are essential for carrying out business operations and maximizing growth and performance. The arrangements are designed to meet growing business demands, accommodate changing product mix, and improve accessibility to patients. The aggregate value of these transactions exceeds 10% of the company's turnover, making them material in nature under SEBI regulations.

Results of the e-voting and the Scrutinizer's report will be made available on the company's website, NSDL's platform, and communicated to the National Stock Exchange of India Limited and BSE Limited where the company's equity shares are listed.

AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Durvalumab Solution for Infusion under the brand name Imfinzi for an additional therapeutic indication. The company announced this development through a regulatory filing dated February 10, 2026.

Regulatory Approval Details

The CDSCO, under the Directorate General of Health Services, Government of India, has granted permission for two formulations of the cancer treatment drug:

Treatment Protocol and Indication

The approved treatment protocol involves a combination therapy approach for endometrial cancer patients. Durvalumab will be used in combination with carboplatin and paclitaxel as first-line treatment for adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.

Following the initial combination treatment, patients will receive maintenance treatment with Durvalumab as monotherapy, specifically for endometrial cancer that is mismatch repair deficient (dMMR). This targeted approach addresses a specific subset of endometrial cancer cases with particular genetic characteristics.

Market Access and Next Steps

The regulatory approval paves the way for AstraZeneca Pharma India to market Imfinzi in India for the specified additional indication. However, the company noted that marketing activities remain subject to obtaining any related statutory approvals that may be required.

This approval expands the therapeutic applications of Imfinzi in the Indian market, potentially providing new treatment options for patients with advanced endometrial cancer. The drug's availability will depend on the completion of any remaining regulatory requirements and the company's commercial launch timeline.